hims glp 1 cost results Hims & Hers stock crashes after FDA announces plans to take "decisive steps" against GLP-1 compounds Hims & Hers tackles high

Key milestones highlighted in this timeline: 1999 Orlistat (Xenical) The first long-term FDA-approved anti-obesity medication of the modern era

Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive

Weight loss, whether resulting from disease-related conditions or intentional interventions, has been increasingly recognized as a significant risk factor for compromised skeletal integrity

Given the heterogeneity of the included evidencespanning case reports, pharmacovigilance analyses, and observational cohortsthis review is framed primarily as a signal-detection and evidence-mapping exercise rather than a causal-inference analysis

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs